Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Phytocannabinoids, including compounds such as cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), interact with the endocannabinoid system, which in turn can influence various neurotransmitter systems in the brain, including dopamine. Scientific research has demonstrated that certain phytocannabinoids can modulate dopamine release and signaling. For example, THC is known to increase dopamine release acutely in the brain's reward pathways, while CBD appears to have modulatory effects and may counteract some of the dopaminergic overstimulation caused by THC. These interactions are relevant for conditions associated with dopamine dysregulation, such as Parkinson’s disease, schizophrenia, and addiction.

Preclinical and clinical studies suggest that phytocannabinoids may influence dopamine-related behaviors and neurochemistry, although the effects can be complex and are highly dose- and compound-dependent. For instance, some studies indicate potential benefits of CBD in reducing psychotic symptoms (which are often linked to dopamine dysregulation), but there is insufficient evidence to conclude that phytocannabinoids broadly or reliably "support" the dopamine system in healthy individuals. Most research focuses on managing symptoms of specific neurological conditions rather than general dopamine support. Overall, the scientific evidence is moderate and specific to certain contexts rather than general wellness support.

More about Phytocannabinoid (unspecified)
More about Dopamine

Other ingredients that support Dopamine

Other body systems supported by Phytocannabinoid (unspecified)

Products containing Phytocannabinoid (unspecified)